What We've Achieved

The partners at Prospect Ventures have led investments in more than 50 companies and have an established track record of working closely with management teams in early and growth stage enterprises. These private and public companies have achieved substantial clinical and commercial success in their industry segments and have generated superior investment returns for Prospect Venture Partners funds. 

Notable investments include Amicus Therapeutics (NASDAQ: FOLD), Amira Pharmaceuticals (NYSE: BMS acquired), Aveo Pharmaceuticals (NASDAQ: AVEO), Cabochon (Merz acquired), Complete Genomics (NASDAQ: GNOM), Gloucester Pharmaceuticals (NASDAQ: CELG acquired), Healtheon (NASDAQ: WBMD merged), Idun Pharmaceuticals (NYSE: PFE acquired), Infinity Pharmaceuticals (NASDAQ: INFI), Intuitive Surgical (NASDAQ: ISRG), Jazz Pharmaceuticals (NASDAQ: JAZZ), Kythera Biopharmaceuticals (NYSE: AGN acquired) Millennium Pharmaceuticals (Takeda Pharmaceutical acquired), NGM Biopharmaceuticals, Ninepoint Medical, Novacept (NASDAQ: HOLX acquired), Opus Medical (NASDAQ: ARTC acquired), Portola Pharmaceuticals (NASDAQ: PTLA), SentreHeart, Rinat Neuroscience (NYSE: PFE acquired), Senomyx (NASDAQ: SNMX), SurgRx (NYSE: JNJ acquired), Tercica (NYSE: IPN acquired), Tinea Pharmaceuticals (NASDAQ: VRX acquired), Transave (NASDAQ: INSM), Trubion (NYSE: EBS acquired), Visiogen (NYSE: ABT acquired) and Vitae Pharmaceuticals (NYSE: AGN acquired).